Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Dual-modality imaging with CEUS and MRI for early recurrence assessment in hepatocellular carcinoma following combined radiofrequency ablation and transarterial chemoembolization. Local targets link to admitted publications; unresolved targets remain external evidence.
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
10.3322/caac.21834 · 2024 · External reference
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
10.1097/hep.0000000000000466 · 2023 · External reference
Trans-arterial chemoembolization plus radiofrequency ablation versus surgical resection in hepatocellular carcinoma: a meta-analysis
10.1016/j.ejso.2020.01.004 · 2020 · External reference
Combined transarterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma infeasible for ultrasound-guided percutaneous radiofrequency ablation: a comparative study with general ultrasound-guided radiofrequency ablation outcomes
10.3390/cancers15215193 · 2023 · External reference
Early recurrence after radiofrequency ablation for hepatocellular carcinoma: a multicenter retrospective study on definition, patterns and risk factors
10.1080/02656736.2020.1849828 · 2021 · External reference
Contrast-enhanced ultrasound in the short-term evaluation of hepatocellular carcinoma after locoregional treatment
10.1159/000506455 · 2020 · External reference
A new proposal for secondary surveillance following potentially curative therapy of HCC: alternating MRI and CEUS
10.1007/s00261-021-03331-1 · 2022 · External reference
Liver imaging reporting and data system contrast-enhanced US nonradiation treatment response assessment version 2024
10.1148/radiol.232369 · 2024 · External reference
Complementary role of CEUS and CT/MR LI-RADS for diagnosis of recurrent HCC
10.3390/cancers15245743 · 2023 · External reference
Evaluating treatment response following locoregional therapy for hepatocellular carcinoma: a review of the available serological and radiological tools for assessment
10.1002/jgh3.12879 · 2023 · External reference
Contrast-enhanced ultrasound in HCC diagnosis and assessment of tumor response to locoregional therapies
10.1007/s00261-021-03059-y · 2021 · External reference
Contrast-enhanced ultrasound for monitoring treatment response in different stages of hepatocellular carcinoma
10.3390/cancers14030481 · 2022 · External reference
Loco-regional treatment of hepatocellular carcinoma: role of contrast-enhanced ultrasonography
10.4254/wjh.v14.i5.911 · 2022 · External reference
The role of diffusion-weighted imaging in locoregional therapy outcome prediction and response assessment for hepatocellular carcinoma: the new era of functional imaging biomarkers
10.3390/diagnostics5040546 · 2015 · External reference
Nodules identified on surveillance ultrasound for HCC: CEUS or MRI as the initial test
10.1002/jum.16183 · 2023 · External reference
Clinical impact of CEUS on non-characterizable observations and observations with intermediate probability of Malignancy on CT/MRI in patients at risk for HCC
10.1007/s00261-024-04305-9 · 2024 · External reference
CT/MRI and CEUS LI-RADS major features association with hepatocellular carcinoma: individual patient data meta-analysis
10.1148/radiol.2021211244 · 2022 · External reference
The diagnostic performance of contrast-enhanced ultrasound for evaluating hepatocellular carcinoma juxtaposed to MRI findings: a retrospective single-center analysis of 292 patients
10.3233/ch-209213 · 2020 · External reference
Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update
10.1159/000514174 · 2021 · External reference
The clinical management of hepatocellular carcinoma worldwide: a concise review and comparison of current guidelines: 2022 update
10.5582/bst.2022.01061 · 2022 · External reference
Comparison of hepatic resection combined with intraoperative radiofrequency ablation, or hepatic resection alone, for hepatocellular carcinoma patients with multifocal tumors meeting the University of California San Francisco criteria: a propensity score-matched analysis
10.1245/s10434-020-08231-0 · 2020 · External reference
Efficacy of fusion imaging and cone-beam computed tomography-guided radiofrequency ablation for hepatocellular carcinoma poorly visualized on ultrasonography
10.1159/000546427 · 2026 · External reference
Intra-procedural CT/MR-ultrasound fusion imaging helps to improve outcomes of thermal ablation for hepatocellular carcinoma: results in 502 nodules
10.1055/a-1021-1616 · 2021 · External reference
Feeding vessel ablation: a novel subsegmental devascularization technique for the treatment of hepatocellular carcinoma located at the liver marginal angle
10.1016/j.ultrasmedbio.2021.11.011 · 2022 · External reference
Thermal ablation of medium-sized hepatocellular carcinomas using intraoperative ultrasound fusion imaging: a propensity score-matched analysis
10.1016/j.clinre.2020.11.011 · 2021 · External reference
Diagnostic performance of [18F]FAPI-04 PET/CT in suspected recurrent hepatocellular carcinoma: prospective comparison with contrast-enhanced CT/MRI
10.1007/s00259-025-07273-4 · 2025 · External reference
Ultrasound-guided percutaneous microwave ablation for hepatocellular carcinoma originating in the caudate lobe: a pilot clinical study
10.4103/jcrt.jcrt_1851_20 · 2021 · External reference
Improving clinical outcomes of patients with hepatocellular carcinoma: role of antiviral therapy, conversion therapy, and palliative therapy
10.4251/wjgo.v16.i10.4037 · 2024 · External reference
